Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counter-balanced by a strong Th2 bias,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counter-balanced by a strong Th2 bias
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2021-05-30 , DOI: 10.1002/cti2.1280
Zeinab Dalloul ₁ , Marie Best ₂ , Pauline Chenuet _{3,

4} , Iman Dalloul ₁ , Sandrine Le Noir ₁ , Dieudonnée Togbé _{3,

4} , Mylène Gador ₂ , Bernhard Ryffel ₃ , Valerie Fj Quesniaux ₃ , Yolla El Makhour ₅ , François Boyer ₁ , Jean-Claude Aldigier ₁ , Jeanne Cook-Moreau ₁ , Nicolas Fazilleau ₂ , Michel Cogné _{1,

6}

Affiliation

Inhibitors of bromodomain and extra terminal domain (BET) proteins are a new and growing class of anti-cancer drugs, which decrease oncogene expression by targeting superenhancers. Antibody production is another physiological process relying on superenhancers, and it remains to be clarified whether potential immunomodulatory properties of BET inhibitors might impact humoral immunity and allergy.

中文翻译：

溴域和末端外 (BET) 蛋白对小鼠 B 细胞中 IgG/IgE 产生的抑制被强烈的 Th2 偏向抵消

溴结构域和额外末端结构域 (BET) 蛋白的抑制剂是一类新的且不断增长的抗癌药物，它们通过靶向超增强剂来降低癌基因的表达。抗体产生是另一个依赖于超级增强剂的生理过程，BET 抑制剂的潜在免疫调节特性是否会影响体液免疫和过敏仍有待阐明。

更新日期：2021-05-31

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文